Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

This study has been completed.
Cystic Fibrosis Foundation
Information provided by:
Altus Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: November 9, 2004
Last updated: March 24, 2010
Last verified: June 2005

The purpose of this study is to determine the most effective dose of a new enzyme therapy on oral nutrient absorption in cystic fibrosis (CF) subjects with exocrine pancreatic insufficiency.

Condition Intervention Phase
Cystic Fibrosis
Pancreatic Insufficiency
Drug: TheraCLEC™ - Total
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency

Resource links provided by NLM:

Further study details as provided by Altus Pharmaceuticals:

Primary Outcome Measures:
  • Coefficient of fat absorption (CFA)

Secondary Outcome Measures:
  • Coefficient of nitrogen absorption (CNA)
  • Weight of stools
  • Number of stools
  • Starch digestion and carbohydrate absorption as measured by blood glucose response
  • Quality of life as measured by the Cystic Fibrosis Questionnaire (CFQ)

Estimated Enrollment: 126
Study Start Date: June 2004
Estimated Study Completion Date: March 2005

Ages Eligible for Study:   7 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Pancreatic insufficiency (PI) documented by fecal elastase <100 mg/gm measured at the Screening Visit
  • Diagnosis of CF based upon the following criteria: *two clinical features consistent with CF; and *either genotype with two identifiable mutations consistent with CF, *or sweat chloride > 60 mEq/L by quantitative pilocarpine iontophoresis.
  • FEV1 > 30% predicted
  • Clinically stable with no evidence of acute upper or lower respiratory tract infection

Exclusion Criteria:

  • Pregnancy, breastfeeding or of childbearing potential and or not willing to use accepted methods of birth control during enrollment in the study
  • History of fibrosing colonopathy
  • History of liver transplant or lung transplant
  • Unable to discontinue enteral tube feedings during the study
  • Subject weight < 40 kg
  • Known hypersensitivity to food additives
  • Participation in an investigational study of a drug, biologic, or device not currently approved for marketing within 30 days prior to the Screening Visit
  • Unable to discontinue the use of pancreatic enzymes for a 72-hour period or any other condition that the investigator believes would interfere with the intent of this study or would make study participation not in the best interest of the subject
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00095732

  Show 27 Study Locations
Sponsors and Collaborators
Altus Pharmaceuticals
Cystic Fibrosis Foundation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00095732     History of Changes
Other Study ID Numbers: TC-2A
Study First Received: November 9, 2004
Last Updated: March 24, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Altus Pharmaceuticals:
Pancreatic Insufficiency
Cystic Fibrosis

Additional relevant MeSH terms:
Cystic Fibrosis
Exocrine Pancreatic Insufficiency
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases

ClinicalTrials.gov processed this record on September 30, 2014